Follow on Google News News By Tag Industry News Country(s) Industry News
Follow on Google News | ATHN, ORFG, REGN, NHPR, PDLI - CRWEWallstreet.com Stock Report! February 21st 2011Orofino Gold Corp. (ORFG.PK)'s mission is to become a 100,000 ounce gold producer from their first mine and to replicate this on each of the current optioned properties.
By: Hanson athenahealth, Inc. engages in the provision of Internet-based business services for physician practices primarily in the United States. Orofino Gold Corp. (ORFG.PK)'s mission is to become a 100,000 ounce gold producer from their first mine and to replicate this on each of the current optioned properties. The vision of Orofino Gold Corp.: * To become a good Joint Venture Partner * To become a premier Mid Tier precious metals mining operation in Colombia * To fast track their first mine to commercial production. ORFG has announced the appointment of Mr. Salvador Rivero to the company's Board of Directors. Mr. Rivero brings to Orofino a wealth of knowledge in the areas of business, corporate finance, and mining operations. After graduating from law school in Mexico, Mr. Rivero spent the next 25 years developing a thorough understanding of the processes necessary to successfully discover, acquire, and develop, mineral concessions with the potential of containing valuable mineral deposits. Considered by Orofino as an acquisitions specialist, Mr. Rivero has been involved in the development of various turn-key projects in mining, energy, fertilizer, oil and gas, and shipping sectors. More about ORFG at:www.orofinogold.com Regeneron Pharmaceuticals, Inc announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones. "2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein occlusion, and one with ARCALYST® for the prevention of gout flares in patients initiating uric-acid lowering therapy," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "We expect regulatory applications to be filed in the first half of 2011 for marketing approval in the U.S. and Europe for VEGF Trap-Eye in wet AMD. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. Now we all know that the uninsured pay more for care-and have less-than those with insurance. However when the uninsured can not pay, health care providers adjust those costs to the who can pay-those which passes the buck to those who have insurance policy. This then leads to higher costs for those who buy the insurance on the particular market, as well as individuals who get insurance coverage for themselves and their own families through their job. The need for affordable healthcare alternatives has never been greater. National Health Partners, Inc. (National Health) (OTCBB-NHPR.OB) National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called “CARExpress.” More about NHPR at: www.nationalhealthpartners.com PDL BioPharma, Inc. announced that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis® and PDL's patents known as the Queen et al. patents. Under the settlement agreement, PDL paid MedImmune $65 million on February 15, 2011 and will pay $27.5 million by February 10, 2012 for a total of $92.5 million. MedImmune has not paid royalties to PDL on sales of Synagis that occurred after September 30, 2009. No further payments will be owed by MedImmune to PDL under its license to the Queen et al. patents as a result of past or future Synagis sales. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Sign Up For Free Stock Alerts At http://crwewallstreet.com/ ************************************************************ THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(Read more at http://crwewallstreet.com/ End
Account Email Address Disclaimer Report Abuse
|
|